Connect with us

Insight

‘Femtech addresses critical unmet needs in the women’s health space’

Published

on

Dr Pamela Walker tells FemTech World everything we need to know about the femtech market.

Can you tell our readers a little bit about yourself?

I am a healthcare strategic growth specialist and award winning MedTech angel investor. I have been passionate about the healthcare space my whole life, and this drive pushed me to complete a PhD in Neuroscience, followed more recently by an Executive MBA (both from Oxford).

I have devoted my career to helping get treatments and medical devices to the patients that need them, and optimising the support patients, caregivers and healthcare professionals need to improve outcomes.

To make this impact, I work with Pharma and MedTech corporates as well as Private Equity and VC funds, advising on acquisitions and optimising commercialisations in the UK, US and worldwide.  I am a Partner at Gate One, heading up the Life Sciences sector, Gate One Incubator and investment channel. I am also an avid investor with THENA Capital and Angel Academe, and board advisor to a number of our portfolio investments.

Why is it important to invest in femtech?

Femtech is an important sector, addressing critical unmet needs in the women’s health space. It leverages tech innovations that we have at our fingertips and applies them to critical gaps in healthcare for over 50 per cent of the world’s population.

In 2021, the gender healthcare gap gained visibility in the UK with the publication of the House of Lords Library report. This report highlights that the UK has the largest female health gap in the G20 and the 12th largest globally. This past summer, NHS England published its strategy on how the gap should be addressed.

Independent reports and inquiries have highlighted where this gap is most visible:

  • Mental health, heart conditions, and pain treatment are some of the areas for which women are not offered the same level of care as men.
  • Women’s health is under researched and is given a lower priority when it comes to health services: less is known about conditions that only affect women including common gynaecological conditions that can have severe impacts on health and wellbeing. For example, it takes seven to eight years for women to receive a diagnosis of endometriosis, with 40% of women needing 10 or more GP appointments before being referred to a specialist.
  • Clinical research in women is dramatically lower than in men, and gender biases in clinical trials are contributing to worse health outcomes for women vs men.

This evidence has highlighted the need for greater focus on women’s health. The market must consider women as a sizeable consumer group. This is an underserved group that is increasingly educated, employed, and receiving attention from diversity and inclusion benchmarks at a global level.

Women represent an important consumer group to be marketed to and a discerning group that will prefer products relevant for them. Companies that consider them will win.

What do you think is missing in the femtech industry?

There are a number of novelty products and me-too solutions in this space, at the moment. Although there are products targeting key points in the female lifecycle, most, however, are still finding their feet. Some are missing a business model for longevity, others are very niche and will struggle to gain uptake, others have unclear value propositions. Overall, evidence of impact hasn’t quite yet pulled through, but there is a lot of excellent innovation kicking off.

From a product development standpoint, design and execution support is needed. There is a medium-term gap to address the gender healthcare gap imbalance through the drug and medical product development process. Innovations that optimise the development process with a gender balanced lens will be in demand.

What do you see in the future of femtech?

Meaningful, purposeful, and effective solutions. Holistic solutions that streamline and simplify tools/support/tech to the issues that matter most to women. These might include:

  • Enablers to improve clinical research by gathering data and partnering with research centres. There is a need to accelerate understanding and research in women’s health whether it leads to better supporting female athletes or better understanding risk factors and treatment outcomes for women.
  • Solutions that optimise pre-post natal and menopause (beyond education and community support) are key. Women have an important role to play in the global economy. At present, we aren’t achieving our full potential. Femtech is pivotal in this space to ensure that those who want, can fully participate and perform in the workforce, whatever stage of life they are at.
  • Remote tech: Health systems are under pressure, solutions that empower women to engage with maintenance/ prevention of their health outside of hospitals (e.g. at home annual testing) are transformational.
  • Innovations for earlier disease (eg cancer) detection: these can help to reduce the need for traumatic and expensive surgeries and treatments.

How can digital tools impact the femtech market?

FemTech by its very name is reliant heavily on tech innovation. Real impact will be:

  • significant builds on current solutions that improve health outcomes and / or the female experience, OR
  • carving out new solutions to unmet need spaces.

Leveraging nascent digital tools and optimising them for the female market (keeping this customer group at the heart of design, production and experience) will be critical to maximise impact.

 

 

 

Dr. Pamela Walker

News

Women shouldering hidden burden of navigating healthcare system – study

Published

on

Women face a hidden burden navigating healthcare, with many repeatedly retelling their medical history, a national study suggests.

The findings indicate that Canadian women are taking on cognitive, emotional and administrative work alongside managing their health, including coordinating providers and advocating for care.

More than half of women surveyed, 53 per cent, reported a past or current chronic condition, while 64 per cent said there were health topics they struggled to raise with their doctor.

Sarah Hoffman, president and CEO of Pacific Blue Cross, said: “These findings challenge us to think differently about women’s healthcare and highlight the hidden work required to navigate the system.

“For many women, managing their health has also come to mean managing the healthcare system itself.

“They are acting as project managers of their own care, shouldering the invisible labour of coordinating between providers, retelling their medical history and advocating to be heard.

 “The gap between men and women is meaningful and raises important questions about why younger women report lower levels of confidence and support.

“It also challenges us to consider whether we are actually making progress in women’s care, and whether the next generation is being equipped with the confidence and voice to advocate for their health.”

Overall, 71 per cent of Canadians described their doctors as supportive and 88 per cent expected their appointments to go well.

Among women living with chronic conditions, 71 per cent reported having to repeat their complete health history multiple times a year.

Younger women were particularly likely to report difficulties discussing their health. The study found 81 per cent of Gen Z women aged 18 to 30 and 73 per cent of Millennial women aged 31 to 45 had health topics they struggled to raise with their doctor.

Among Gen Z women with chronic illness, 92 per cent reported having to repeat their complete health history.

The study also found differences between young women and men. While 95 per cent of Gen Z men expected a doctor’s appointment to go well, the figure was 82 per cent among Gen Z women.

Similarly, 82 per cent of Gen Z men said they felt supported by their family doctor, compared with 66 per cent of Gen Z women.

Reasons for holding back health concerns varied between generations.

Among Gen Z women, 30 per cent cited fear of dismissal and 29 per cent fear of judgement.

Embarrassment was the most common barrier among Millennial, Gen X and Boomer women, reported by 29 per cent, 27 per cent and 35 per cent respectively.

Women who felt they needed to prove themselves to be taken seriously said they adapted how they approached appointments.

Strategies included researching medical information, repeatedly describing or justifying symptoms, bringing written notes or documentation, tracking symptom timelines, making repeat visits and emphasising how symptoms affected their daily lives.

The study also found an association between feeling supported by a doctor and expecting appointments to go well.

Canadians who described their physician as supportive were nearly four times more likely to expect appointments to go well than those who felt unsupported, at 98 per cent compared with 25 per cent.

Overall, 66 per cent of Canadians said they described their symptoms accurately. This fell to 48 per cent among those who said they felt unsupported by their doctor.

The 2026 Blue Cross Women’s Health Study surveyed 2,045 adult Canadians online in March 2026 through independent research company Research + Knowledge = Insights.

The survey had a reported margin of error of plus or minus 2 per cent, 19 times out of 20.

Continue Reading

Insight

Court recognises radiation as factor in flight attendant’s breast cancer

Published

on

A French court has linked cosmic radiation to a former flight attendant’s breast cancer for the first time.

Sophie Lainault, 59, had sought to have her cancer recognised as an occupational disease linked to her working conditions.

The court in Bayonne ruled that cosmic radiation was one of three carcinogenic, or cancer-causing, hazards arising from her profession, alongside passive smoking and prolonged night work.

Smoking was authorised on Air France flights until 2000.

The ruling means Lainault, who is in remission, can take early retirement and have any further treatment fully reimbursed by the French health system.

Lawyers said the decision has also cleared the way for similar claims by recognising breast cancer as an occupational risk for flight crews.

Lainault said: “My dearest wish is that the decision encourages other women who up until now have not had the courage to take this step.”

Lainault worked as a stewardess and later a purser on Air France aircraft, recording 12,600 flight hours between 1989 and 2019. More than half of those hours were at night.

Many of her long-distance, high-altitude flights from Paris would have taken her near the North Pole, where exposure to cosmic radiation is most intense.

Cosmic radiation consists of particles originating from the sun and other stars.

A study this month at Harvard Medical School in the US involving more than 500 professions found that flight attendants and pilots had the highest proportions of radiation-related cancer deaths.

About 6.9 per cent of deaths among flight attendants and 6.7 per cent among pilots were from radiation-related cancers, according to the analysis.

The proportions were higher than in other professions, including nuclear technologists, who are routinely exposed to radiation from non-cosmic sources and ranked 12th in the analysis.

It has long been known that high-altitude air travel exposes people to cosmic radiation, although the dose received by most travellers is regarded as statistically insignificant. Exposure is higher at the poles because elsewhere the Earth’s magnetic field acts as a shield.

Lainault’s lawyer Elisabeth Leroux said: “In France the link between breast cancer and certain hazards has been established for a number of professions, such as nurses … but this is the first time for an air-hostess.”

Air France said it had not been involved in Lainault’s legal case and had not seen the reasoning behind the court’s decision.

“The health and security of our staff is an absolute imperative,” the airline said. “Every employee has a medical accompaniment that goes well beyond the regulatory minimum.”

Continue Reading

Insight

Study to tackle years-long delays in endometriosis diagnosis

Published

on

A study is examining where delays occur in diagnosing endometriosis  – a condition that can take seven to twelve years to diagnose.

Endometriosis affects an estimated 1.5 million women and people in the UK, but there is currently no consistent way of measuring where and why diagnostic delays happen.

The research aims to develop the first standardised framework for understanding the diagnostic journey and identifying points where interventions could improve care.

The international project involves researchers from the University of Sheffield, University of Liverpool, University of Oxford, Aarhus University in Denmark and the University of Edinburgh, alongside Endometriosis UK.

Dr Rebecca Mawson, NIHR clinical lecturer in primary care at the University of Sheffield, is part of the research team.

She said: “Our project asks: where exactly are people getting lost or let down on their journey to diagnosis, and how can we map those points in a systematic way to identify where interventions could make a real difference.”

The project is led by Dr Babu Karavadra, NIHR academic clinical fellow in general practice at the University of Liverpool, who has been awarded a World Endometriosis Society Early Career Investigator Award as lead principal investigator at the University of Liverpool.

Researchers will review existing evidence, gather experiences from people living with endometriosis and bring together an international panel to map the diagnostic pathway and agree common definitions for key points along the journey.

The work will focus particularly on people whose experiences are often missing from research, including Black women, people living in rural or deprived areas, LGBTQ+ communities and disabled people.

Primary care will also be central to the research because it is often where people first seek help with symptoms.

Mawson said: “Primary care needs to be at the heart of this work. Primary care is often where people first seek help with their symptoms, so it has a crucial role in understanding diagnostic delay.

“If we only look at what happens once someone reaches specialist gynaecology, we risk missing some of the barriers that shape the journey long before that point.”

Unlike cancer research, where internationally recognised standards exist for studying diagnostic delays, endometriosis research has been more fragmented, with studies measuring different parts of the diagnostic journey in different ways.

The researchers hope to create an ‘Endometriosis Diagnostic Pathway Framework’ to help identify where people are falling through the gaps and where healthcare could be improved.

They will also develop a ‘Snakes and Ladders’ style visual representation showing how systemic barriers, chance and individual experiences can influence whether someone reaches a diagnosis.

The project forms part of the PEARL network, Primary care Endometriosis and Adenomyosis Research and Learning, an international collaboration of primary care and community researchers and clinicians.

Mawson said: “Endometriosis diagnostic delay isn’t inevitable. If we can understand where and why people are experiencing barriers, we have a much better chance of designing interventions that actually make a difference.

“The scale of the problem demands that we look at the whole journey, listen to the people experiencing it and build an evidence base that can lead to real change.”

The framework could provide the foundations for future research, clinical guideline development, healthcare professional training and NHS service improvements, with potential applications to related conditions such as adenomyosis and chronic pelvic pain.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.